[Translation] A randomized, double-blind, bridging safety and efficacy study of PF-06439535 (CN) combined with paclitaxel-carboplatin in Chinese participants with advanced non-squamous non-small cell lung cancer
基于描述性估计 PF-06439535(CN) 和贝伐珠单抗-EU的客观缓解率 (ORR) 来探索两者在疗效上的相似性,两者均与紫杉醇和卡铂联合应用。除此之外,还将评估安全性、PK 和免疫原性。
[Translation] Similarities in efficacy were explored based on descriptive estimates of objective response rate (ORR) for PF-06439535(CN) and bevacizumab-EU, both in combination with paclitaxel and carboplatin. In addition to this, safety, PK and immunogenicity will be assessed.